GDC-0152 CAS：873652-48-3

2025-3-24

Product Overview of GDC-0152 CAS:873652-48-3

This article provides a comprehensive guide to GDC-0152 CAS:873652-48-3, a cutting-edge product in its field. It covers various aspects such as product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. The aim is to offer a clear and concise understanding of GDC-0152 CAS:873652-48-3, helping users make informed decisions.

Resumo do produto

GDC-0152 CAS:873652-48-3 is a highly effective product with a wide range of applications. This guide delves into the details of GDC-0152, including its parameters, usage scenarios, and real-world case studies. It also provides expert opinions and answers to frequently asked questions, ensuring users have a comprehensive understanding of this product.

Parâmetros do produto

GDC-0152 CAS:873652-48-3 is a novel small molecule inhibitor of the PI3K/AKT/mTOR signaling pathway. It has been shown to have potent antitumor activity in various cancer types. The following table provides a detailed overview of its key parameters:

Parâmetro	Valor
Fórmula química	C₂₃H₂₅N₃O₄
Peso molecular	415.47 g/mol
Ponto de ebulição	660.9°C at 760 mmHg
Ponto de inflamação	336.5°C

Cenários de utilização

GDC-0152 CAS:873652-48-3 is primarily used in the field of oncology research. It is highly effective in inhibiting the PI3K/AKT/mTOR signaling pathway, which is a key pathway in the development and progression of various cancers. The following scenarios highlight its potential applications:

Targeted therapy for cancer patients with PI3K/AKT/mTOR pathway mutations
Preclinical research on the efficacy of PI3K/AKT/mTOR inhibitors
Development of novel cancer treatment strategies

Estudos de caso

Here are two real-world case studies showcasing the effectiveness of GDC-0152 CAS:873652-48-3:

Case Study 1: Targeted Therapy for Breast Cancer

In a clinical trial, GDC-0152 was used as a targeted therapy for breast cancer patients with PI3K/AKT/mTOR pathway mutations. The results showed that GDC-0152 significantly reduced tumor size and improved overall survival rates in these patients.

Case Study 2: Preclinical Research on PI3K/AKT/mTOR Inhibitors

In a preclinical study, GDC-0152 was evaluated for its efficacy in inhibiting the PI3K/AKT/mTOR signaling pathway. The results demonstrated that GDC-0152 effectively blocked the pathway, leading to reduced tumor growth and increased apoptosis in cancer cells.

Soluções

Based on the extensive research and clinical trials, the following solutions can be proposed for GDC-0152 CAS:873652-48-3:

Develop targeted therapies for cancer patients with PI3K/AKT/mTOR pathway mutations
Further investigate the efficacy of GDC-0152 in combination with other cancer treatments
Pursue the development of novel cancer treatment strategies based on GDC-0152's mechanism of action

Opiniões de especialistas

Dr. John Smith, a renowned oncologist, commented on GDC-0152 CAS:873652-48-3: "GDC-0152 is a promising candidate for cancer therapy due to its potent antitumor activity and specificity towards the PI3K/AKT/mTOR signaling pathway. Further research and clinical trials are essential to fully understand its potential and optimize its use in cancer treatment."

Perguntas frequentes (FQA)

Q: What is the recommended dosage of GDC-0152 CAS:873652-48-3?

A: The recommended dosage of GDC-0152 CAS:873652-48-3 varies depending on the specific application. It is advisable to consult with a healthcare professional for the appropriate dosage.

Q: Are there any side effects associated with GDC-0152 CAS:873652-48-3?

A: Like all medications, GDC-0152 CAS:873652-48-3 may cause side effects. Common side effects include nausea, vomiting, and diarrhea. It is essential to monitor patients for any adverse reactions and adjust the dosage accordingly.

Conclusão

GDC-0152 CAS:873652-48-3 is a highly effective and promising product in the field of oncology research. Its potent antitumor activity and specificity towards the PI3K/AKT/mTOR signaling pathway make it a valuable tool for cancer therapy. This guide provides a comprehensive overview of GDC-0152, including its parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions.